SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 4

Tenascin-C ve oksidatif stresin romatizmal ve konjenital kalp kapak hastalığındaki rolü: Gözlemsel bir çalışma

The role of tenascin-C and oxidative stress in rheumatic and congenital heart valve diseases: an observational study

Fatih SAP
Tamer BAYSAL
Hümeyra ÇİÇEKLER
Zehra KARATAŞ
Hakan ALTIN
Pages
350–356
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Serum TnC level of the patients with rheumatic HVD [median 9.09 (0.94-46.30) ng/mL] was significantly higher than both congenital HVD and control groups [median 2.97 (0.66-11.80) ng/mL; p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to evaluate the association of tenascin-C (TnC) and total oxidant-antioxidant status to rheumatic or con- genital heart valve diseases (HVD) in pediatric patients.
📊
Key Findings & Data:Methods: Fifty pediatric patients (25 rheumatic HVD patients and 25 congenital HVD patients) and 20 healthy age-matched control subjects, aged 3-17 years, were enrolled in this observational and cross-sectional study.
💡
Conclusion & Impact:Results: Serum TnC level of the patients with rheumatic HVD [median 9.09 (0.94-46.30) ng/mL] was significantly higher than both congenital HVD and control groups [median 2.97 (0.66-11.80) ng/mL; p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to evaluate the association of tenascin-C (TnC) and total oxidant-antioxidant status to rheumatic or con- genital heart valve diseases (HVD) in pediatric patients. Methods: Fifty pediatric patients (25 rheumatic HVD patients and 25 congenital HVD patients) and 20 healthy age-matched control subjects, aged 3-17 years, were enrolled in this observational and cross-sectional study. Serum total antioxidant capacity (TAC), total oxidant status (TOS), oxidative stress index (OSI) and TnC levels were compared among the groups. ANOVA and Kruskal-Wallis tests were used for statistical analysis. Results: Serum TnC level of the patients with rheumatic HVD [median 9.09 (0.94-46.30) ng/mL] was significantly higher than both congenital HVD and control groups [median 2.97 (0.66-11.80) ng/mL; p

Özet

Amaç: Bu çalışmanın amacı çocukluk döneminde romatizmal veya konjenital kapak hastalıklarının serum tenascin-C (TnC) ve total oksidan-antiok- sidan seviyeleri ile ilişkisini değerlendirmektir. Yöntemler: Yaşları 3-17 arasındaki 50 çocuk hasta (25 romatizmal kapak hastası, 25 konjenital kapak hastası) ile yaşça uyumlu 20 sağlıklı birey bu enine kesitli ve gözlemsel çalışmaya alındı. Tenascin-C, total anti-oksidan kapasite (TAC), total oksidan seviye (TOS) ve oksidatif stres indeks (OSİ) değerleri gruplar arasında karşılaştırıldı. Gruplar arası karşılaştırmalarda ANOVA ve Kruskal-Wallis testi kullanıldı. Bulgular: Romatizmal kalp hastalığı grubunun TnC düzeyleri [ortanca 9.09 (0.94-46.30) ng/mL] konjenital ve kontrol gruplarından yüksek bulundu [sırasıyla ortanca 2.97 (0.66-11.80) ng/mL, p

🔖

Cite This Article

SAP, F., BAYSAL, T., ÇİÇEKLER, H., KARATAŞ, Z., ALTIN, H. (2022). Tenascin-C ve oksidatif stresin romatizmal ve konjenital kalp kapak hastalığındaki rolü: Gözlemsel bir çalışma. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 4, 350–356. https://ajindex.com/articles/436181

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lincoln J, Yutzey KE. Molecular and developmental mechanisms of congenital heart valve disease. Birth Defects Res A Clin Mol Teratol 2011
  2. [CrossRef] 2. Davutoğlu V, Çelik A, Aksoy M. Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class. J Heart Valve Dis 2005
  3. Gölbaşı Z, Uçar O, Keleş T, Şahin A, Çağlı K, Çamsarı A, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail 2002
  4. [CrossRef] 4. Tani LY. Rheumatic Fever and Rheumatic Heart Disease. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF, editors. Moss and Adam’s Heart Disease in Infants, Children and Adolescents, 7th ed. Philadelphia: Lippincott Williams and Wilkins
  5. p.1256-80. 5. Guilherme L, Kalil J. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 2010
  6. [CrossRef] 6. Fan H, Liu W, Yan P Pathological observation and immunohistochemistry study of Type I, III, IV collagen in mitral valve and cardiac interstitium of rheumatic disease. Zhonghua Yi Xue Za Zhi 1996
  7. Udalova IA, Ruhmann M, Thomson SJ, Midwood KS. Expression and immune function of tenascin-C. Crit Rev Immunol 2011
  8. [CrossRef] 8. Golledge J, Clancy P Maguire J, Lincz L, Koblar S. The role of tenascin C in cardiovascular disease. Cardiovasc Res 2011
  9. [CrossRef] 9. Jian B, Jones PL, Li Q, Mohler ER 3rd, Schoen FJ, Levy RJ. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 2001
  10. [CrossRef] 10. Satta J, Melkko J, Pöllänen R, Tuukkanen J, Pääkkö P Ohtonen P et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol 2002
  11. [CrossRef] 11. Jiang L, Wei XF, Yi DH, Xu P Liu H, Chang Q, et al. Synergistic effects of cyclic strain and Th1-like cytokines on tenascin-C production by rheumatic aortic valve interstitial cells. Clin Exp Immunol 2009
  12. [CrossRef] 12. Chiavaroli V, Giannini C, De Marco S, Chiarelli F, Mohn A. Unbalanced oxidant-antioxidant status and its effects in pediatric diseases. Redox Rep 2011
  13. [CrossRef] 13. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic